Improving Animal Model of Induced Colitis by Acetic Acid in Terms of Fibrosis and Inflammation Incidence in the Colon

Bahrami, Gholamreza; Malekshahi, Hossein; Miraghaee, Shahram; Madani, Hamid; Babaei, Atefeh

doi:10.1080/08941939.2020.1821844

Cited by 14 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beginning of pharmacological intervention after colitis induction is another variable to be considered as a factor that produces experimental heterogeneity. In models with lower inductive strength, induced colitis tends to spontaneously disappear after some days [78]. In our study, the time that animals remain induced varied from 1 to 21 days.…”

Section: Discussionmentioning

confidence: 92%

Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review

Ferreira‐Duarte

Tonin

Duarte‐Araújo

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

BackgroundThe renin‐angiotensin system (RAS) has been associated with inflammatory bowel disease (IBD), supporting translational relevance of RAS blockers. Comparability of study design/outcomes is fundamental for data analysis/discussion.ObjectivesWe aimed at evaluating the heterogeneity among protocols and outcomes to study the effect of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers in IBD.MethodsThis study was performed and reported in accordance with the Cochrane recommendations and PRISMA (PROSPERO‐CRD42022323853). Systematic searches were performed in PubMed, Scopus and Web of Science. Studies that met the inclusion criteria were selected. Quality assessment of the studies was done with the SYRCLES's risk of bias tools for animal studies.ResultsThirty‐five pre‐clinical studies and six clinical studies were included. Chemical induction of colitis was the most used model, but variable doses of the induction agent were reported. All studies reported at least a disease activity index, a macroscopic score, or a histologic assessment, but these scores were methodologically heterogeneous and reported for different characteristics. Great heterogeneity was also found in drug interventions. Inflammatory markers assessed as outcomes were different across studies.ConclusionLack of standardization of protocols and outcomes among studies threatens the evidence on how RAS blockers influence IBD outcomes.

show abstract

Section: Discussionmentioning

confidence: 92%

Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review

Ferreira‐Duarte

Tonin

Duarte‐Araújo

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Previous research has yielded a plethora of scenarios regarding the various mechanisms involved in colitis ( Bahrami et al, 2022 ), with oxidative stress being demonstrated to play an important role ( Pereira et al, 2015 ). During chronic and acute intestinal inflammation, macrophages and neutrophils destroy local tissue by secreting tissue degrading enzymes and reactive oxygen species (ROS) ( Rieder et al, 2007 ).…”

Section: Discussionmentioning

confidence: 99%

“…Inflammation is another pathogenic scenario implicated in AA-induced colitis ( Saber et al, 2021c ; Bahrami et al, 2022 ). There is a close relationship between inflammation and oxidative stress ( Abdelhamid et al, 2021a ; Abdelhamid et al, 2021b ), where oxidative stress is connected to UC exacerbation by stimulating the overexpression of proinflammatory proteins, hence increasing inflammatory responses ( Bahrami et al, 2022 ). The NFκB signaling pathway has been reported to be activated by AA-administration ( Viennois et al, 2012 ; Rezayat et al, 2018 ; Rashidian et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis

et al. 2022

View full text Add to dashboard Cite

Ulcerative colitis (UC), an inflammatory bowel disease, is a chronic condition of a multifaceted pathophysiology. The incidence of UC is increasing internationally. The current therapies for UC lack relative effectiveness and are associated with adverse effects. Therefore, novel therapeutic options should be developed. It has been well documented that modulating the Nrf2/NFκB is a promising therapeutic target in inflammation. Carbocisteine is a mucoregulatory medication and its efficacy in COPD was found to be more closely related to its antioxidant and anti-inflammatory properties. Carbocisteine has not yet been examined for the management of UC. Hence, our approach was to investigate the potential coloprotective role of carbocisteine in acetic acid-induced colitis in rats. Our results revealed that carbocisteine improved colon histology and macroscopic features and subdued the disease activity as well. Additionally, carbocisteine attenuated colon shortening and augmented colon antioxidant defense mechanisms via upregulating catalase and HO-1 enzymes. The myeloperoxidase activity was suppressed indicating inhibition of the neutrophil infiltration and activation. Consistent with these findings, carbocisteine boosted Nrf2 expression along with NFκB inactivation. Consequently, carbocisteine downregulated the proinflammatory cytokines IL-6 and TNF-α and upregulated the anti-inflammatory cytokine IL-10. Concomitant to these protective roles, carbocisteine displayed anti-apoptotic properties as revealed by the reduction in the Bax: BCL-2 ratio. In conclusion, carbocisteine inhibited oxidative stress, inflammatory response, and apoptosis in acetic acid-induced UC by modulating the Nrf2/HO-1 and NFκB interplay in rats. Therefore, the current study provides a potential basis for repurposing a safe and a commonly used mucoregulator for the treatment of UC.

show abstract

“…Some studies reported that acetic acid can reduce inflammation and antiviral infection by activating the G-protein-coupled receptor GPR43, mediating NF-κb activation and inducing IFN-β production in lung epithelial cells ( Antunes et al, 2019 ). However, other studies had shown that acetic acid could induce the release of pro-inflammatory cytokines, increase the calprotectin released by neutrophils under inflammatory conditions, and cause colon tissue damage due to leukocyte infiltration into the surface epithelium ( Bahrami et al, 2020 ; Bastaki et al, 2021 ). Therefore, the intervention mechanism of XFBD may be related to the regulation of intestinal microecological homeostasis and the level of SCFAs, but further research is needed in the follow-up.…”

Section: Discussionmentioning

confidence: 99%

Modulating effect of Xuanfei Baidu granule on host metabolism and gut microbiome in rats

Shi

Xing

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Xuanfei Baidu granule (XFBD) is a recommended patented drug for the prevention and treatment of Corona Virus Disease 2019 (COVID-19), which is approved by the National Medical Products Administration. XFBD suppresses the over-activated immune response caused by inflammatory factor storms in COVID-19 infection. The intestine plays a crucial role in the immune system. The mass spectrometry based fecal metabolomics with 16S rDNA sequencing were combined to evaluate the effects of XFBD on host metabolism and gut microbiome. Short-chain fatty acids (SCFAs) contents in fecal matter were quantified by gas chromatography-mass spectrometry (GC-MS). Plasma samples were used to detect immune and inflammatory levels. The results were verified with a rat model of intestinal disorder. Results indicated that XFBD could increase the immune level of Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) (p < 0.05). The OPLS-DA analysis results showed that a total of 271 differential metabolites (178 up-regulated and 93 down-regulated) were identified based on the VIP ≥1, p < 0.05, FC ≥ 2 and FC ≤ 0.5. The metabolic pathways mainly involved D-Glutamine and D-glutamate metabolism, Arginine biosynthesis, Biotin metabolism, et al. XFBD modified the gut bacteria structure according to the principal component analysis (PCA), that is, 2 phyla, 3 classes, 5 orders, 11 families and 14 genera were significantly different based on taxonomic assignment. In addition, it could partially callback the relative abundance of intestinal microflora in bacterial disorder rats caused by antibiotics. It is suggested that the intervention mechanism of XFBD might be related to the regulation of intestinal flora composition. The evidence obtained in the study provides a useful reference for understanding the mechanism of XFBD.

show abstract

Improving Animal Model of Induced Colitis by Acetic Acid in Terms of Fibrosis and Inflammation Incidence in the Colon

Cited by 14 publications

References 29 publications

Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review

Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review

Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis

Modulating effect of Xuanfei Baidu granule on host metabolism and gut microbiome in rats

Contact Info

Product

Resources

About